Dodaro Concetta Anna, Calogero Armando, Tammaro Vincenzo, Pellegrino Tommaso, Lionetti Ruggero, Campanile Silvia, Menkulazi Marsela, Ciccozzi Massimo, Iannicelli Anna Maria, Giallauria Francesco, Sagnelli Caterina
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Department of Public Health, University of Naples Federico II, Naples, Italy.
Open Med (Wars). 2019 Aug 14;14:607-612. doi: 10.1515/med-2019-0068. eCollection 2019.
Neoadjuvant chemoradiotherapy has a significant role in downstaging cancer. It improves the local control of the disease and can make conservative resection of rectal cancer possible.
We enrolled 114 patients with subperitoneal rectal cancer who underwent neoadjuvant chemoradio-therapy and radical excision with total mesorectal excision (TME). The primary endpoint was oncological outcomes and the secondary endpoint was surgical outcomes.We evaluate the experience of a multidisciplinary team and the role of neoadjuvant chemoradiotherapy in integrated treatment of cancer of the subperitoneal rectum.
Surgical procedures performed were abdominal perineal resection in 4 cases (3.5%), anterior resection in 89 cases (78%), Hartmann's procedure in 5 cases (4.4%), and ultralow resection with coloanal anastomosis and diverting stoma in 16 patients (14%).Local recurrence occurred in 6 patients (5.2%), the overall survival was 71.9% at 5 years and disease-free survival was about 60%.
The effect of pathological downstaging amounted to 58.8%, including cPR. The pathologic complete remission occurred in 8.8% of cases.The outcomes of neoadjuvant therapy can be achieved when this treatment is associated with correct surgical technique with TME and the prognosis is defined by an anatomopathological examination performed according to Quirke's protocol.
新辅助放化疗在降低癌症分期方面具有重要作用。它可改善疾病的局部控制,并使直肠癌的保肛手术成为可能。
我们纳入了114例接受新辅助放化疗及全直肠系膜切除术(TME)根治性切除的腹膜下直肠癌患者。主要终点是肿瘤学结局,次要终点是手术结局。我们评估了多学科团队的经验以及新辅助放化疗在腹膜下直肠癌综合治疗中的作用。
所施行的手术方式中,4例(3.5%)为腹会阴联合切除术,89例(78%)为前切除术,5例(4.4%)为Hartmann手术,16例(14%)为超低位切除并结肠肛管吻合及转流造口术。6例(5.2%)出现局部复发,5年总生存率为71.9%,无病生存率约为60%。
病理降期效果达58.8%,包括临床完全缓解(cPR)。8.8%的病例出现病理完全缓解。当这种治疗与正确的TME手术技术相结合时,可实现新辅助治疗的效果,且预后由根据奎克方案进行的解剖病理学检查确定。